Obinutuzumab

Red

Brand Name(s):Gazyvaro

Indication:Chronic lymphocytic leukaemia (CLL)
Follicular Lymphoma (FL)

Rationale:1,2

Considered:Aug-14

Review Date:Aug-25

Comments:
NICE TA629 recommends Obinutuzumab with bendamustine followed by obinutuzumab maintenance, as an option for treating follicular lymphoma that has not responded or progressed up to 6 months after treatment with rituximab or a rituximab-containing regimen. …………………………Obinutuzumab with bendamustine for treating follicular lymphoma after rituximab- guidance (TA629)